Debjit Chattopadhyay
Stock Analyst at Guggenheim
(4.61)
# 230
Out of 5,001 analysts
104
Total ratings
58.95%
Success rate
22.42%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Debjit Chattopadhyay
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| QURE uniQure | Maintains: Buy | $28 → $95 | $58.37 | +62.75% | 7 | Sep 25, 2025 | |
| PEPG PepGen | Reiterates: Buy | $6 | $4.62 | +29.87% | 2 | Sep 24, 2025 | |
| IONS Ionis Pharmaceuticals | Maintains: Buy | $90 → $92 | $65.42 | +40.63% | 6 | Sep 23, 2025 | |
| RZLT Rezolute | Reiterates: Buy | $15 | $9.40 | +59.57% | 3 | Sep 22, 2025 | |
| SRPT Sarepta Therapeutics | Reiterates: Buy | $22 | $19.27 | +14.17% | 6 | Sep 15, 2025 | |
| MAZE Maze Therapeutics | Maintains: Buy | $19 → $34 | $25.93 | +31.12% | 3 | Sep 15, 2025 | |
| SLNO Soleno Therapeutics | Reiterates: Buy | $106 | $67.60 | +56.80% | 5 | Aug 27, 2025 | |
| PASG Passage Bio | Maintains: Buy | $40 → $10 | $8.00 | +25.00% | 3 | Aug 14, 2025 | |
| BMRN BioMarin Pharmaceutical | Maintains: Buy | $101 → $106 | $54.16 | +95.72% | 4 | Aug 6, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Buy | $558 → $546 | $391.64 | +39.41% | 8 | Aug 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $64 | $30.08 | +112.77% | 3 | Jun 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $50 | $12.65 | +295.26% | 5 | Jun 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $55 → $45 | $17.27 | +160.57% | 2 | May 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $195 → $189 | $176.53 | +7.06% | 4 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $78 → $55 | $24.27 | +126.62% | 3 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $28 | $24.25 | +15.46% | 6 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $18 | $5.54 | +224.91% | 3 | Dec 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $17 | $14.01 | +21.34% | 2 | Dec 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $15 | $7.88 | +90.36% | 2 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | n/a | $64.81 | - | 1 | Jun 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $19 | $5.52 | +244.20% | 2 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $4.67 | +371.09% | 1 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $30 | $28.44 | +5.49% | 1 | Jan 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $29 | $1.24 | +2,238.71% | 1 | Nov 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $456.00 | - | 1 | Jun 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $3.27 | +756.27% | 1 | Dec 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $20 | $7.32 | +173.22% | 2 | Dec 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $270 → $123 | $34.60 | +255.49% | 8 | Aug 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $54 | $17.08 | +216.16% | 3 | Jul 9, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $60 | $1.23 | +4,778.05% | 3 | Dec 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $40.14 | - | 3 | Jun 26, 2017 |
uniQure
Sep 25, 2025
Maintains: Buy
Price Target: $28 → $95
Current: $58.37
Upside: +62.75%
PepGen
Sep 24, 2025
Reiterates: Buy
Price Target: $6
Current: $4.62
Upside: +29.87%
Ionis Pharmaceuticals
Sep 23, 2025
Maintains: Buy
Price Target: $90 → $92
Current: $65.42
Upside: +40.63%
Rezolute
Sep 22, 2025
Reiterates: Buy
Price Target: $15
Current: $9.40
Upside: +59.57%
Sarepta Therapeutics
Sep 15, 2025
Reiterates: Buy
Price Target: $22
Current: $19.27
Upside: +14.17%
Maze Therapeutics
Sep 15, 2025
Maintains: Buy
Price Target: $19 → $34
Current: $25.93
Upside: +31.12%
Soleno Therapeutics
Aug 27, 2025
Reiterates: Buy
Price Target: $106
Current: $67.60
Upside: +56.80%
Passage Bio
Aug 14, 2025
Maintains: Buy
Price Target: $40 → $10
Current: $8.00
Upside: +25.00%
BioMarin Pharmaceutical
Aug 6, 2025
Maintains: Buy
Price Target: $101 → $106
Current: $54.16
Upside: +95.72%
Vertex Pharmaceuticals
Aug 6, 2025
Maintains: Buy
Price Target: $558 → $546
Current: $391.64
Upside: +39.41%
Jun 20, 2025
Reiterates: Buy
Price Target: $64
Current: $30.08
Upside: +112.77%
Jun 18, 2025
Reiterates: Buy
Price Target: $50
Current: $12.65
Upside: +295.26%
May 12, 2025
Maintains: Buy
Price Target: $55 → $45
Current: $17.27
Upside: +160.57%
May 7, 2025
Maintains: Buy
Price Target: $195 → $189
Current: $176.53
Upside: +7.06%
May 7, 2025
Maintains: Buy
Price Target: $78 → $55
Current: $24.27
Upside: +126.62%
Mar 26, 2025
Reiterates: Buy
Price Target: $28
Current: $24.25
Upside: +15.46%
Dec 3, 2024
Reiterates: Buy
Price Target: $18
Current: $5.54
Upside: +224.91%
Dec 3, 2024
Reiterates: Buy
Price Target: $17
Current: $14.01
Upside: +21.34%
Nov 7, 2024
Maintains: Buy
Price Target: $13 → $15
Current: $7.88
Upside: +90.36%
Jun 28, 2024
Assumes: Neutral
Price Target: n/a
Current: $64.81
Upside: -
Apr 30, 2024
Initiates: Buy
Price Target: $19
Current: $5.52
Upside: +244.20%
Mar 26, 2024
Initiates: Buy
Price Target: $22
Current: $4.67
Upside: +371.09%
Jan 18, 2024
Initiates: Buy
Price Target: $30
Current: $28.44
Upside: +5.49%
Nov 21, 2022
Maintains: Buy
Price Target: $43 → $29
Current: $1.24
Upside: +2,238.71%
Jun 27, 2022
Downgrades: Neutral
Price Target: n/a
Current: $456.00
Upside: -
Dec 16, 2021
Initiates: Buy
Price Target: $28
Current: $3.27
Upside: +756.27%
Dec 15, 2020
Assumes: Buy
Price Target: $20
Current: $7.32
Upside: +173.22%
Aug 24, 2020
Downgrades: Neutral
Price Target: $270 → $123
Current: $34.60
Upside: +255.49%
Jul 9, 2020
Maintains: Buy
Price Target: $60 → $54
Current: $17.08
Upside: +216.16%
Dec 3, 2019
Downgrades: Neutral
Price Target: $60
Current: $1.23
Upside: +4,778.05%
Jun 26, 2017
Downgrades: Neutral
Price Target: n/a
Current: $40.14
Upside: -